The 36-month beta value for PCVX is at 0.90. Analysts have varying views on the stock, with 5 analysts rating it as a “buy,” 5 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PCVX is 116.65M, and currently, shorts hold a 8.83% of that float. The average trading volume for PCVX on September 20, 2024 was 1.02M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
PCVX) stock’s latest price update
The stock price of Vaxcyte Inc (NASDAQ: PCVX) has surged by 0.50 when compared to previous closing price of 116.54, but the company has seen a 2.62% gain in its stock price over the last five trading sessions. globenewswire.com reported 2024-09-11 that SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Wednesday, September 18, at 10:20 a.m. ET / 7:20 a.m. PT.
PCVX’s Market Performance
PCVX’s stock has risen by 2.62% in the past week, with a monthly rise of 48.23% and a quarterly rise of 60.97%. The volatility ratio for the week is 3.35% while the volatility levels for the last 30 days are 3.90% for Vaxcyte Inc The simple moving average for the past 20 days is 17.14% for PCVX’s stock, with a 61.01% simple moving average for the past 200 days.
Analysts’ Opinion of PCVX
Many brokerage firms have already submitted their reports for PCVX stocks, with Mizuho repeating the rating for PCVX by listing it as a “Buy.” The predicted price for PCVX in the upcoming period, according to Mizuho is $69 based on the research report published on December 07, 2023 of the previous year 2023.
Needham gave a rating of “Buy” to PCVX, setting the target price at $58 in the report published on January 03rd of the previous year.
PCVX Trading at 33.45% from the 50-Day Moving Average
After a stumble in the market that brought PCVX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -1.99% of loss for the given period.
Volatility was left at 3.90%, however, over the last 30 days, the volatility rate increased by 3.35%, as shares surge +46.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +44.63% upper at present.
During the last 5 trading sessions, PCVX rose by +2.62%, which changed the moving average for the period of 200-days by +117.65% in comparison to the 20-day moving average, which settled at $101.85. In addition, Vaxcyte Inc saw 86.50% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PCVX starting from GUGGENHIME ANDREW, who sale 8,000 shares at the price of $115.94 back on Sep 18 ’24. After this action, GUGGENHIME ANDREW now owns 90,383 shares of Vaxcyte Inc, valued at $927,551 using the latest closing price.
Loxam Teri, the Director of Vaxcyte Inc, sale 6,250 shares at $116.28 during a trade that took place back on Sep 17 ’24, which means that Loxam Teri is holding 7,175 shares at $726,731 based on the most recent closing price.
Stock Fundamentals for PCVX
Current profitability levels for the company are sitting at:
- -34.76 for the present operating margin
- 0.17 for the gross margin
The net margin for Vaxcyte Inc stands at -34.42. The total capital return value is set at -0.25. Equity return is now at value -29.08, with -27.70 for asset returns.
Based on Vaxcyte Inc (PCVX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -18.25. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -46.8.
Currently, EBITDA for the company is -382.87 million with net debt to EBITDA at 1.01. When we switch over and look at the enterprise to sales, we see a ratio of 953.38. The receivables turnover for the company is 0.81for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 17.88.
Conclusion
In conclusion, Vaxcyte Inc (PCVX) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
